165 related articles for article (PubMed ID: 23511711)
1. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
2. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
3. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
5. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
6. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
7. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
8. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
9. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E; Nafziger AN; Kazierad DJ; Bertino JS
Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
[TBL] [Abstract][Full Text] [Related]
10. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
Stoch SA; Friedman E; Maes A; Yee K; Xu Y; Larson P; Fitzgerald M; Chodakewitz J; Wagner JA
J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
Greenblatt DJ; Peters DE; Oleson LE; Harmatz JS; MacNab MW; Berkowitz N; Zinny MA; Court MH
Br J Clin Pharmacol; 2009 Dec; 68(6):920-7. PubMed ID: 20002087
[TBL] [Abstract][Full Text] [Related]
13. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
[TBL] [Abstract][Full Text] [Related]
15. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
16. Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
Friedman EJ; Fraser IP; Wang YH; Bergman AJ; Li CC; Larson PJ; Chodakewitz J; Wagner JA; Stoch SA
J Clin Pharmacol; 2011 Nov; 51(11):1561-70. PubMed ID: 21209240
[TBL] [Abstract][Full Text] [Related]
17. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
[TBL] [Abstract][Full Text] [Related]
18. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
Vuppugalla R; Zhang Y; Chang S; Rodrigues AD; Marathe PH
Xenobiotica; 2012 Nov; 42(11):1058-68. PubMed ID: 22574883
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.
KuKanich B; Hubin M
J Vet Pharmacol Ther; 2010 Feb; 33(1):42-9. PubMed ID: 20444024
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
Li WL; Xin HW; Su MW
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]